# Crossover, Single Dose, Two-stage Bioequivalence Study of SCMC-Lys Salt 1.35 g Powder vs SCMC-Lys Salt 90 mg/mL Syrup

> **NCT02858193** · PHASE1 · COMPLETED · sponsor: **Dompé Farmaceutici S.p.A** · enrollment: 30 (actual)

## Conditions studied

- Bronchitis

## Interventions

- **DRUG:** SCMC-lys powder 1.35 g
- **DRUG:** Fluifort® syrup

## Key facts

- **NCT ID:** NCT02858193
- **Lead sponsor:** Dompé Farmaceutici S.p.A
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-04
- **Primary completion:** 2016-07-25
- **Final completion:** 2016-10-10
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02858193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02858193, "Crossover, Single Dose, Two-stage Bioequivalence Study of SCMC-Lys Salt 1.35 g Powder vs SCMC-Lys Salt 90 mg/mL Syrup". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02858193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*